AcelRx commences dosing in ARX-04 sufentanil NanoTab Phase 2 research for breakthrough and acute pain AcelRx Pharmaceuticals, Inc. , a specialty pharmaceutical firm focused on the advancement and commercialization of innovative treatments for the treating acute and breakthrough discomfort, today announced that it offers dosed the first subjects in a Phase 2, placebo-controlled, dose-finding research of its ARX-04 sufentanil NanoTab product applicant.S. Army Medical Materiel and Research Command, or USAMRMC.6 million grant to aid the advancement of ARX-04, a proprietary non-invasive, fast-onset sublingual item candidate for the treating moderate-to-severe acute pain.Â..However, not surprisingly alarming trend, recognition, education, indicators and early treatment can make a big change and help keep these sportsmen in the game, based on the scholarly study experts. Year-round sports activities and increased exposure leading to more adolescent sport-related accidents Thomas M. DeBerardino, MD, an orthopaedic surgeon focusing on sports medicine for the University of Connecticut Huskies and Associate Professor of Orthopaedics at the University of Connecticut Wellness Middle, moderated an instructional course at AAOS annual meeting, titled ‘Athletic Injuries in the Adolescent Athlete.’ Relating to Dr. DeBerardino, adolescent sport-related accidental injuries are increasing, so much so that they have become a ‘silent epidemic.’ ‘Even more adolescents are participating in year-round sports activities without seasonal breaks, or they are concurrently playing on multiple groups,’ he says.